Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Area of Science:

• Oncology
• Immunology
• Medicinal Chemistry

Background:

• Tumor cells evade immune surveillance via immune checkpoints like PD-1/PD-L1.
• Antibodies targeting PD-1/PD-L1 have shown success in cancer treatment.
• Limitations of antibodies drive interest in small molecule inhibitors.

Purpose of the Study:

• To review small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.
• To categorize inhibitors based on their therapeutic approach.
• To highlight novel avenues for cancer immunotherapy.

Main Methods:

• Literature review of small molecule inhibitors.
• Categorization based on three distinct mechanisms of action.
• Analysis of therapeutic strategies against PD-1/PD-L1.

Main Results:

• Identified small molecule inhibitors targeting PD-1/PD-L1 interactions.
• Summarized inhibitors that inhibit PD-L1 transcription and translation.
• Highlighted inhibitors promoting PD-L1 protein degradation.

Conclusions:

• Small molecule inhibitors represent a promising alternative to antibodies for PD-1/PD-L1 targeted therapy.
• These inhibitors offer diverse strategies to overcome tumor immune escape.
• Development of small molecule inhibitors opens new avenues in tumor immunotherapy.